Login
Azora Therapeutics, Inc. (DE) logo

Azora Therapeutics, Inc. (DE)

adial.com

What Do They Do?

Develops an investigational treatment for alcohol use disorder in patients with specified genetic subgroups.

How Do They Make Money?

No revenue reported yet.

How Are They Changing?

Since the FY2025 annual report
  • Oct 28, 2026 Azora acquisition shifts focus to ulcerative colitis drug development Stockholders approved conversion of preferred stock issued in the acquisition; the company appointed a new CEO and CFO.

Purnovate leaves the portfolio The earlier report described Purnovate's adenosine drug-discovery platform as part of its portfolio; the latest centers on its lead addiction-treatment candidate and says Purnovate's assets and business were sold.

From commercialization to clinical development The earlier report described a focus on commercializing its lead candidate in the U.S. and Europe; the latest describes completing clinical development, primarily for U.S. regulatory requirements, with Europe and the UK secondary.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support